Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
WALTHAM, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced a partnership with Population Health Partners, L.P. (PHP) a global life-science firm dedicated to solving the health and economic challenges presented by prevalent diseases. Through the partnership, Invivyd will leverage PHP’s best-in-class clinical development and regulatory expertise to help optimize Invivyd’s product development programs.
- Through the partnership, Invivyd will leverage PHPs best-in-class clinical development and regulatory expertise to help optimize Invivyds product development programs.
- PHP has great experience in helping organizations like ours overcome the industry challenges inherent in navigating trials focused on large population medicine.
- We are excited to work with PHP and its leadership team at this pivotal point in the evolution of our company.
- Population Health Partners, L.P. is an investment firm committed to building great companies around important, late-stage therapeutics and solving the health and economic challenges presented by prevalent diseases.